Short-term (1-2 mo) hormone therapy cessation before mammography

Menopause

Volumn 16, Issue 6, 2009, Pages 1125-1131

  Reed, Susan D ^a,b   Buist, Diana S M ^a   Anderson, Melissa L ^a   Aiello Bowles, Erin J ^a   Fitzgibbons, Dawn ^a   Seger, Deborah ^a   Newton, Katherine M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Estrogen and progestin therapy (EPT) cessation; Estrogen therapy (ET) cessation; Hormone therapy cessation; Mammographic screening; Mammography performance

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST; BREAST CANCER; CANCER RISK; CANCER SCREENING; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DRUG MEGADOSE; EDUCATION; ETHNICITY; FAMILY HISTORY; FEMALE; GROUPS BY AGE; HEALTH CARE PLANNING; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INTEGRATED HEALTH CARE SYSTEM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSAL SYNDROME; RACE; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SHORT COURSE THERAPY; SYMPTOM; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; BREAST; BREAST NEOPLASMS; EDUCATIONAL STATUS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LOGISTIC MODELS; MAMMOGRAPHY; MIDDLE AGED; PATIENT SELECTION; POSTMENOPAUSE; PROGESTINS; QUESTIONNAIRES; SENSITIVITY AND SPECIFICITY;

EID: 73249142068     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181a5ce60     Document Type: Article

References (25)

1. Boudreau DM, Buist DS, Rutter CM, Fishman PA, Beverly KR, Taplin S. Impact of hormone therapy on false-positive recall and costs among women undergoing screening mammography. Med Care 2006;44:62-69.
2. Harvey JA, Pinkerton JV, Herman CR. Short-term cessation of hormone replacement therapy and improvement of mammographic specificity. J Natl Cancer Inst 1997;89:1623-1625. (Pubitemid 27479724)
3. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004; 104: 1042-1050. (Pubitemid 40458772)
4. Collaborative Group on Hormone Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-1059.
5. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin, on breast cancer and mammography in healthy postmenopausal women: the Women's Health. Initiative randomized trial. JAMA 2003;289:3243-3253. (Pubitemid 37430077)
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
7. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003; 138:168-175.
8. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) investigators. Ann Intern Med 1999;130:262-269.
9. Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 1996;88:643-649. (Pubitemid 26152550)
10. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women.: Women's Health Initiative randomized trial. J Natl Cancer Inst 2005;97:1366-1376. (Pubitemid 41487804)
11. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-176. (Pubitemid 32048518)
12. Taplin SH, Thompson RS, Schnitzer F, Anderman C, Immanuel V. Revisions in the risk-based Breast Cancer Screening Program at Group Health Cooperative. Cancer 1990;66:812-818. (Pubitemid 20281331)
13. Taplin SH, Ichikawa L, Buist DS, Seger D, White E. Evaluating organized breast cancer screening implementation: the prevention of latestage disease? Cancer Epidemiol Biomarkers Prev 2004;13:225-234. (Pubitemid 38222553)
14. Group Health Breast Cancer Surveillance, Center for Health Studies. Breast Cancer Surveillance, Center for Health Studies. Available at: http: //www.centerforhealthstudies.org/surveillanceproject/public/screening html. Accessed December 15, 2008.
15. National Center Institute. Breast Cancer Risk Assessment Tool. An Interactive Tool for Measuring the Risk of Invasive Breast Cancer. Available at: http://www.cancer.gov/bcrisktool/. Accessed December 15, 2008.
16. Barber CA, Margolis K, Luepker RV, Amett DK. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002). J. Womens Health (Larchmt) 2004;13:975-985. (Pubitemid 40017335)
17. Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 1999; 6:282-289. (Pubitemid 30003270)
18. Buick DL, Crook D, Home R. Women's perceptions of hormone replacement therapy: risks and benefits (1980-2002). A. literature review. Climacteric 2005;8:24-35.
19. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712. (Pubitemid 38489892)
20. Bosworth HB, Bastian LA, Grambow SC, et al. Initiation and discontinuation of hormone therapy for menopausal symptoms: results from a community sample. J Behav Med 2005;28:105-114.
21. Ness J, Aronow WS. Prevalence and causes of persistent use of hormone replacement therapy among postmenopausal women: a follow-up study. Am J Ther 2006;13:109-112. (Pubitemid 43755118)
22. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. Am J Med 2005;118:163-165.
23. Howard BV, Kuller L, Langer R, et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative observational study. Circulation 2005;111:1456-1458. (Pubitemid 40470639)
24. Ceausu I, Shakir YA, Lidfeldt J, Samsioe G, Nerbrand C. The hysterectomized woman. Is she special? The Women's Health in the Lund Area (WHILA) study. Maturitas 2006;53:201-209. (Pubitemid 41820514)
25. Buist DM, Anderson ML, Reed SD, et al. Effects of suspending hormone therapy for 1-2 months on mammography performance and mammographic breast density: results from the Radiological Evaluation and Breast Density (READ) randomized trial. Ann Intern Med. In press.